MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Allogene Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.36 -6.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.31

Max

1.45

Pagrindiniai rodikliai

By Trading Economics

Pajamos

6.4M

-60M

Pelnas, tenkantis vienai akcijai

-0.28

Darbuotojai

226

EBITDA

6.8M

-56M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+520.44% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-12

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-92M

365M

Ankstesnė atidarymo kaina

7.57

Ankstesnė uždarymo kaina

1.36

Naujienos nuotaikos

By Acuity

12%

88%

21 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Allogene Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-01 23:46; UTC

Rinkos pokalbiai

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-04-01 23:43; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025-04-01 23:11; UTC

Svarbiausios naujienos

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025-04-01 23:02; UTC

Rinkos pokalbiai

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 22:26; UTC

Rinkos pokalbiai

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:32; UTC

Svarbiausios naujienos

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025-04-01 21:06; UTC

Rinkos pokalbiai

Mexican Remittances See Slow Start to the Year -- Market Talk

2025-04-01 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-04-01 20:47; UTC

Svarbiausios naujienos

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025-04-01 20:47; UTC

Svarbiausios naujienos

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025-04-01 20:20; UTC

Svarbiausios naujienos

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025-04-01 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Fibrebond >ETN

2025-04-01 20:11; UTC

Rinkos pokalbiai

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025-04-01 20:00; UTC

Svarbiausios naujienos

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025-04-01 19:46; UTC

Svarbiausios naujienos

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025-04-01 19:43; UTC

Rinkos pokalbiai

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025-04-01 19:17; UTC

Svarbiausios naujienos

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025-04-01 19:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025-04-01 19:03; UTC

Rinkos pokalbiai

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025-04-01 19:00; UTC

Rinkos pokalbiai

Gold Slips Ahead of Tariff Day -- Market Talk

2025-04-01 18:54; UTC

Rinkos pokalbiai

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Allogene Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

520.44% į viršų

12 mėnesių prognozė

Vidutinis 8.5 USD  520.44%

Aukščiausias 14 USD

Žemiausias 4 USD

Remiantis 12 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Allogene Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

12 ratings

11

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 1.69Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

21 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.